Contemporary Cardiac Issues in Duchenne Muscular Dystrophy
暂无分享,去创建一个
E. Hoffman | D. Judge | G. Pearson | S. Raman | C. Canter | J. Kaltman | K. Kinnett | L. Cripe | D. Duan | C. Spurney | K. Wagner | W. Groh | D. Benson | J. Rafael-Fortney | E. McNally | J. Metzger | J. Finder | S. Targum | N. Kertesz | Jill A. Rafael-Fortney | Roxanne Kirsch | L. Markham | Roxanne E Kirsch | E. P. Hoffman | Shari L. Targum
[1] S. Raman,et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial , 2015, The Lancet Neurology.
[2] Francesco Muntoni,et al. The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases , 2014, European Journal of Human Genetics.
[3] Kristy Brown,et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.
[4] D. Kass,et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy , 2014, Annals of neurology.
[5] J. Vissing,et al. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy , 2014, Annals of neurology.
[6] C. Spurney,et al. Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy , 2014, Muscle & nerve.
[7] B. Wong,et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy , 2014, Neuromuscular Disorders.
[8] S. Nelson,et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy , 2014, Neurology.
[9] S. Etheridge,et al. Predictive Value of Myocardial Delayed Enhancement in Duchenne Muscular Dystrophy , 2014, Pediatric Cardiology.
[10] D. Nonneman,et al. Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin‐glycoprotein complex assembly in pig skeletal muscle , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] P. ’. ‘t Hoen,et al. Fibronectin is a serum biomarker for Duchenne muscular dystrophy , 2014, Proteomics. Clinical applications.
[12] B. Wong,et al. Implantation of the HeartMate II and HeartWare Left Ventricular Assist Devices in Patients With Duchenne Muscular Dystrophy: Lessons Learned From the First Applications , 2014, ASAIO journal.
[13] J. Finsterer,et al. Treatment of dystrophin cardiomyopathies , 2014, Nature Reviews Cardiology.
[14] S. Raman,et al. Prednisolone Attenuates Improvement of Cardiac and Skeletal Contractile Function and Histopathology by Lisinopril and Spironolactone in the mdx Mouse Model of Duchenne Muscular Dystrophy , 2014, PloS one.
[15] S. Raman,et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function , 2013, Journal of Cardiovascular Magnetic Resonance.
[16] S. Colan,et al. A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy , 2013, PLoS currents.
[17] H. Peay. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? , 2013, Neurology.
[18] R. Wanke,et al. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. , 2013, Human molecular genetics.
[19] S. Pandya,et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. , 2013, The Journal of pediatrics.
[20] L. Cripe,et al. Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy , 2013, Paediatric anaesthesia.
[21] T. Partridge. The mdx mouse model as a surrogate for Duchenne muscular dystrophy , 2013, The FEBS journal.
[22] Jerry R Mendell,et al. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy , 2013, Muscle & nerve.
[23] N. Dahdah,et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. , 2013, Journal of the American College of Cardiology.
[24] K. Wollinsky,et al. Long-term ventilation of patients with Duchenne muscular dystrophy: experiences at the Neuromuscular Centre Ulm , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[25] R. Elashoff,et al. Tadalafil Alleviates Muscle Ischemia in Patients with Becker Muscular Dystrophy , 2012, Science Translational Medicine.
[26] E. Hoffman,et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. , 2012, Physical medicine and rehabilitation clinics of North America.
[27] G. Geller,et al. Ethical Challenges in the Care of Children and Families Affected by Life-Limiting Neuromuscular Diseases , 2012, Journal of developmental and behavioral pediatrics : JDBP.
[28] J. Mendell,et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. , 2012, The American journal of cardiology.
[29] L. Markham,et al. Correlation of Heart Rate and Cardiac Dysfunction in Duchenne Muscular Dystrophy , 2012, Pediatric Cardiology.
[30] AbdallahFayssoil. Letter by Fayssoil Regarding Article, “Early Treatment With Lisinopril and Spironolactone Preserves Cardiac and Skeletal Muscle in Duchenne Muscular Dystrophy Mice” , 2012 .
[31] H. Peay,et al. DuchenneConnect Registry Report , 2012, PLoS currents.
[32] D. Duan,et al. Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs , 2011, Neuromuscular Disorders.
[33] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[34] J. Beavo,et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy , 2010, Proceedings of the National Academy of Sciences.
[35] R. Finkel,et al. Widening gap in age at muscular dystrophy–associated death between blacks and whites, 1986–2005 , 2010, Neurology.
[36] J. Wansapura,et al. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. , 2010, The American journal of cardiology.
[37] J. Kornegay,et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. , 2010, The Journal of clinical investigation.
[38] Craig McDonald,et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care , 2010, The Lancet Neurology.
[39] R. Finkel,et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.
[40] Livija Medne,et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.
[41] S. Pandya,et al. Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. , 2009, MMWR. Morbidity and mortality weekly report.
[42] Charlotte M Druschel,et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). , 2009, The Journal of pediatrics.
[43] G. MacGowan,et al. Contrasting effects of steroids and angiotensin‐converting‐enzyme inhibitors in a mouse model of dystrophin‐deficient cardiomyopathy , 2009, European journal of heart failure.
[44] J. Wansapura,et al. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. , 2009, Journal of the American College of Cardiology.
[45] D. Duan,et al. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice. , 2009, Human molecular genetics.
[46] Y. Ishikawa,et al. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. , 2009, Journal of Cardiology.
[47] G. MacGowan,et al. Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy. , 2008, Cardiovascular research.
[48] F. Muntoni,et al. Update on the management of Duchenne muscular dystrophy , 2008, Archives of Disease in Childhood.
[49] S. Colan,et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. , 2008, American heart journal.
[50] C. Des Rosiers,et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency , 2008, Proceedings of the National Academy of Sciences.
[51] B. Wong,et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy , 2008, Neuromuscular Disorders.
[52] D. Duan,et al. Prevention of Dystrophin-Deficient Cardiomyopathy in Twenty-One-Month-Old Carrier Mice by Mosaic Dystrophin Expression or Complementary Dystrophin/Utrophin Expression , 2008, Circulation research.
[53] D. Goudie,et al. Life expectancy and death from cardiomyopathy amongst carriers of Duchenne and Becker muscular dystrophy in Scotland , 2007, Heart.
[54] Chris Feudtner,et al. Collaborative communication in pediatric palliative care: a foundation for problem-solving and decision-making. , 2007, Pediatric clinics of North America.
[55] R. Holubkov,et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. , 2007, JAMA.
[56] A. Toutain,et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. , 2007, American heart journal.
[57] J. Chamberlain,et al. Dystrophin‐deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] E. McNally,et al. Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. , 2007, Trends in cardiovascular medicine.
[59] E. McNally. New approaches in the therapy of cardiomyopathy in muscular dystrophy. , 2007, Annual review of medicine.
[60] D. Duan. Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. , 2006, Human molecular genetics.
[61] K. Okumura,et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[62] Jeroen J. Bax,et al. Effect of Posterolateral Scar Tissue on Clinical and Echocardiographic Improvement After Cardiac Resynchronization Therapy , 2006, Circulation.
[63] J. Newburger,et al. Cardiovascular Health Supervision for Individuals Affected by Duchenne or Becker Muscular Dystrophy , 2005, Pediatrics.
[64] J. Belmont,et al. Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular Dystrophy , 2005, Circulation.
[65] S. Day,et al. Dystrophic heart failure blocked by membrane sealant poloxamer , 2005, Nature.
[66] B. Wong,et al. Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy , 2005, Pediatric Cardiology.
[67] H. Bécane,et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. , 2005, Journal of the American College of Cardiology.
[68] F. Lallemand,et al. Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. , 2004, European heart journal.
[69] B. Wong,et al. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings , 2004, Neuromuscular Disorders.
[70] D. E. Kuhn,et al. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature , 2003, Neuromuscular Disorders.
[71] J. Bourke,et al. 107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands , 2003, Neuromuscular Disorders.
[72] Colin Chandler,et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation , 2002, Neuromuscular Disorders.
[73] A. Comtois,et al. Dystrophin‐deficient cardiomyocytes are abnormally vulnerable to mechanical stress‐induced contractile failure and injury , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[74] D. Yellon,et al. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. , 1987, Cardiovascular research.
[75] T. Matsumura,et al. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. , 2010, Internal medicine.
[76] A. Manzur,et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.